This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Janssen wins Mylan ANDA row as US appeals court affirms infringement

( March 28, 2025, 23:01 GMT | Official Statement) -- MLex Summary: The US Court of Appeals for the Federal Circuit found in favor of Jannsen Pharmaceuticals in its patent row with Mylan Laboratories, affirming a District of New Jersey decision that Mylan's generic for a Janssen medication is likely to induce infringement. The panel found that Janssen's patent for its schizophrenia medication Invega Trinza is not invalid, and that Mylan's label is likely to induce infringement.See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections